跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-01AI 评分40

#EASD26:Boehringer 减肥候选药在糖尿病与肥胖领域落后于竞品

#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity

AI 导读

Boehringer Ingelheim 的领先肥胖候选药物在针对合并 2 型糖尿病患者的晚期临床试验中,诱发体重减轻高达 9.8%。该数据表明其在糖尿病与肥胖领域疗效落后于竞品。

正文

MI­LAN — Boehringer In­gel­heim’s lead obe­si­ty can­di­date prompt­ed weight loss of up to 9.8% in a late-stage tri­al in pa­tients with both obe­si­ty and type 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news